STOCK TITAN

[144] Wave Life Sciences Ltd. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Wave Life Sciences Ltd. (WVE) Form 144 notice: An intended sale of 25,000 common shares is being reported with Morgan Stanley Smith Barney listed as the broker and an approximate aggregate market value of $244,000. The filing shows 159,140,460 shares outstanding and an approximate sale date of 08/22/2025. The shares were acquired on 03/05/2025 through previously exercised stock options and payment was made in cash on the same date. The filer also disclosed a prior sale within the past three months: 30,000 common shares sold on 06/13/2025 under a 10b5-1 plan for gross proceeds of $208,602. The notice includes the standard signature attestations that the seller is not aware of undisclosed material adverse information and references Rule 10b5-1 where applicable.

Avviso Form 144 di Wave Life Sciences Ltd. (WVE): È segnalata l'intenzione di vendere 25.000 azioni ordinarie, con Morgan Stanley Smith Barney indicato come broker e un valore di mercato aggregato approssimativo di $244.000. La comunicazione riporta 159.140.460 azioni in circolazione e una data di vendita prevista per il 22/08/2025. Le azioni sono state acquisite il 05/03/2025 tramite opzioni su azioni già esercitate e il pagamento è stato effettuato in contanti nella stessa data. Il dichiarante ha inoltre reso noto una vendita precedente negli ultimi tre mesi: 30.000 azioni ordinarie vendute il 13/06/2025 nell'ambito di un piano 10b5-1 per ricavi lordi di $208.602. L'avviso include le consuete attestazioni firmate che dichiarano che il venditore non è a conoscenza di informazioni rilevanti non divulgate e fa riferimento alla Regola 10b5-1 ove applicabile.

Aviso Form 144 de Wave Life Sciences Ltd. (WVE): Se informa de la intención de vender 25.000 acciones ordinarias, con Morgan Stanley Smith Barney como corredor y un valor de mercado agregado aproximado de $244,000. La presentación muestra 159.140.460 acciones en circulación y una fecha estimada de venta para el 22/08/2025. Las acciones se adquirieron el 05/03/2025 mediante opciones sobre acciones ya ejercidas y el pago se realizó en efectivo en la misma fecha. El declarante también divulgó una venta previa en los últimos tres meses: 30.000 acciones ordinarias vendidas el 13/06/2025 bajo un plan 10b5-1 por ingresos brutos de $208.602. El aviso incluye las firmas de rutina que certifican que el vendedor no conoce información adversa material no divulgada y hace referencia a la Regla 10b5-1 cuando procede.

Wave Life Sciences Ltd. (WVE) Form 144 공시: Morgan Stanley Smith Barney를 중개인으로 하여 25,000 보통주 매도를 계획하고 있으며, 대략적인 총 시가액 $244,000으로 보고되었습니다. 서류에는 발행주식수가 159,140,460주로 기재되어 있고, 예상 매도일은 2025/08/22로 표시되어 있습니다. 해당 주식은 2025/03/05에 이미 행사된 주식매수옵션을 통해 취득되었고, 동일한 날짜에 현금으로 대금이 지급되었습니다. 제출인은 또한 최근 3개월 내 이전 매도 내역을 공개했는데, 30,000 보통주2025/06/13에 10b5-1 계획에 따라 매도하여 총수익 $208,602를 얻었습니다. 공시에는 매도자가 미공개 중대한 불리한 정보를 알고 있지 않음을 확인하는 표준 서명 진술과 적용 가능한 경우 규칙 10b5-1에 대한 언급이 포함되어 있습니다.

Avis Form 144 de Wave Life Sciences Ltd. (WVE) : Une vente prévue de 25 000 actions ordinaires est signalée, Morgan Stanley Smith Barney étant indiqué comme courtier et une valeur de marché agrégée approximative de 244 000 $. Le dépôt indique 159 140 460 actions en circulation et une date de vente approximative au 22/08/2025. Les actions ont été acquises le 05/03/2025 via des options sur actions précédemment exercées et le paiement a été effectué en espèces à la même date. Le déclarant a également divulgué une vente antérieure au cours des trois derniers mois : 30 000 actions ordinaires vendues le 13/06/2025 dans le cadre d'un plan 10b5-1 pour des produits bruts de 208 602 $. L'avis comprend les attestations de signature habituelles indiquant que le vendeur n'a pas connaissance d'informations défavorables importantes non divulguées et renvoie à la règle 10b5-1 le cas échéant.

Form 144-Mitteilung von Wave Life Sciences Ltd. (WVE): Es wird ein geplanter Verkauf von 25.000 Stammaktien gemeldet, wobei Morgan Stanley Smith Barney als Broker angegeben ist und ein ungefährer aggregierter Marktwert von $244.000 verzeichnet wird. Die Einreichung zeigt 159.140.460 ausstehende Aktien und ein ungefähres Verkaufsdatum am 22.08.2025. Die Aktien wurden am 05.03.2025 durch zuvor ausgeübte Aktienoptionen erworben und am selben Tag in Bargeld bezahlt. Der Meldende gab außerdem einen früheren Verkauf innerhalb der letzten drei Monate an: 30.000 Stammaktien, verkauft am 13.06.2025 im Rahmen eines 10b5-1-Plans für Bruttoerlöse von $208.602. Die Mitteilung enthält die üblichen Unterschriftsbestätigungen, dass dem Verkäufer keine nicht offenbarten wesentlichen nachteiligen Informationen bekannt sind, sowie gegebenenfalls einen Verweis auf Regel 10b5-1.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine insider transaction: exercised options sold via broker; size appears modest relative to outstanding shares.

The Form 144 documents a proposed sale of 25,000 common shares acquired through exercised stock options and paid in cash on the acquisition date. The use of a broker and an indicated sale date are consistent with a compliance-driven disposition rather than an operational disclosure. A 10b5-1 plan sale of 30,000 shares three months earlier is disclosed, indicating prior prearranged selling activity. There are no earnings figures, debt changes, or operational events disclosed in this filing to alter a company valuation. Impact on investors is limited unless aggregate insider selling is materially larger than disclosed here.

TL;DR: Proper procedural filing showing exercised-option sale and prior 10b5-1 activity; no governance red flags presented.

The filing shows the seller represented compliance with disclosure rules and, if relying on a trading plan, referenced Rule 10b5-1 procedures. The transaction was funded in cash at exercise and is being routed through a broker for public sale. No resignations, related-party transactions, or undisclosed arrangements are stated. From a governance standpoint, the document is a standard notice of proposed sale with required attestations and does not present material governance concerns by itself.

Avviso Form 144 di Wave Life Sciences Ltd. (WVE): È segnalata l'intenzione di vendere 25.000 azioni ordinarie, con Morgan Stanley Smith Barney indicato come broker e un valore di mercato aggregato approssimativo di $244.000. La comunicazione riporta 159.140.460 azioni in circolazione e una data di vendita prevista per il 22/08/2025. Le azioni sono state acquisite il 05/03/2025 tramite opzioni su azioni già esercitate e il pagamento è stato effettuato in contanti nella stessa data. Il dichiarante ha inoltre reso noto una vendita precedente negli ultimi tre mesi: 30.000 azioni ordinarie vendute il 13/06/2025 nell'ambito di un piano 10b5-1 per ricavi lordi di $208.602. L'avviso include le consuete attestazioni firmate che dichiarano che il venditore non è a conoscenza di informazioni rilevanti non divulgate e fa riferimento alla Regola 10b5-1 ove applicabile.

Aviso Form 144 de Wave Life Sciences Ltd. (WVE): Se informa de la intención de vender 25.000 acciones ordinarias, con Morgan Stanley Smith Barney como corredor y un valor de mercado agregado aproximado de $244,000. La presentación muestra 159.140.460 acciones en circulación y una fecha estimada de venta para el 22/08/2025. Las acciones se adquirieron el 05/03/2025 mediante opciones sobre acciones ya ejercidas y el pago se realizó en efectivo en la misma fecha. El declarante también divulgó una venta previa en los últimos tres meses: 30.000 acciones ordinarias vendidas el 13/06/2025 bajo un plan 10b5-1 por ingresos brutos de $208.602. El aviso incluye las firmas de rutina que certifican que el vendedor no conoce información adversa material no divulgada y hace referencia a la Regla 10b5-1 cuando procede.

Wave Life Sciences Ltd. (WVE) Form 144 공시: Morgan Stanley Smith Barney를 중개인으로 하여 25,000 보통주 매도를 계획하고 있으며, 대략적인 총 시가액 $244,000으로 보고되었습니다. 서류에는 발행주식수가 159,140,460주로 기재되어 있고, 예상 매도일은 2025/08/22로 표시되어 있습니다. 해당 주식은 2025/03/05에 이미 행사된 주식매수옵션을 통해 취득되었고, 동일한 날짜에 현금으로 대금이 지급되었습니다. 제출인은 또한 최근 3개월 내 이전 매도 내역을 공개했는데, 30,000 보통주2025/06/13에 10b5-1 계획에 따라 매도하여 총수익 $208,602를 얻었습니다. 공시에는 매도자가 미공개 중대한 불리한 정보를 알고 있지 않음을 확인하는 표준 서명 진술과 적용 가능한 경우 규칙 10b5-1에 대한 언급이 포함되어 있습니다.

Avis Form 144 de Wave Life Sciences Ltd. (WVE) : Une vente prévue de 25 000 actions ordinaires est signalée, Morgan Stanley Smith Barney étant indiqué comme courtier et une valeur de marché agrégée approximative de 244 000 $. Le dépôt indique 159 140 460 actions en circulation et une date de vente approximative au 22/08/2025. Les actions ont été acquises le 05/03/2025 via des options sur actions précédemment exercées et le paiement a été effectué en espèces à la même date. Le déclarant a également divulgué une vente antérieure au cours des trois derniers mois : 30 000 actions ordinaires vendues le 13/06/2025 dans le cadre d'un plan 10b5-1 pour des produits bruts de 208 602 $. L'avis comprend les attestations de signature habituelles indiquant que le vendeur n'a pas connaissance d'informations défavorables importantes non divulguées et renvoie à la règle 10b5-1 le cas échéant.

Form 144-Mitteilung von Wave Life Sciences Ltd. (WVE): Es wird ein geplanter Verkauf von 25.000 Stammaktien gemeldet, wobei Morgan Stanley Smith Barney als Broker angegeben ist und ein ungefährer aggregierter Marktwert von $244.000 verzeichnet wird. Die Einreichung zeigt 159.140.460 ausstehende Aktien und ein ungefähres Verkaufsdatum am 22.08.2025. Die Aktien wurden am 05.03.2025 durch zuvor ausgeübte Aktienoptionen erworben und am selben Tag in Bargeld bezahlt. Der Meldende gab außerdem einen früheren Verkauf innerhalb der letzten drei Monate an: 30.000 Stammaktien, verkauft am 13.06.2025 im Rahmen eines 10b5-1-Plans für Bruttoerlöse von $208.602. Die Mitteilung enthält die üblichen Unterschriftsbestätigungen, dass dem Verkäufer keine nicht offenbarten wesentlichen nachteiligen Informationen bekannt sind, sowie gegebenenfalls einen Verweis auf Regel 10b5-1.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What shares does the WVE Form 144 propose to sell?

The notice proposes sale of 25,000 common shares with an aggregate market value of $244,000.

When is the approximate sale date reported on the WVE Form 144?

The filing lists an approximate sale date of 08/22/2025.

How were the 25,000 shares acquired according to the filing?

The shares were acquired on 03/05/2025 through previously exercised stock options and paid for in cash on that date.

Were there any recent sales by the same person disclosed in the Form 144?

Yes. The filing discloses a prior 10b5-1 sale of 30,000 common shares on 06/13/2025 for gross proceeds of $208,602.

What broker is listed for the proposed sale in the Form 144?

The broker named in the filing is Morgan Stanley Smith Barney LLC.
Wave Life Scienc

NASDAQ:WVE

WVE Rankings

WVE Latest News

WVE Latest SEC Filings

WVE Stock Data

1.50B
133.86M
15.93%
86.83%
10.1%
Biotechnology
Pharmaceutical Preparations
Link
Singapore
SINGAPORE